EVO756 not checked

Evommune, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
4 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Migraine
Main trialPhase 2
“This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.”In the company’s words, NCT07616128 on ClinicalTrials.gov

Other drugs for Migraine

All 14 drugs for Migraine

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Oct 2027 Study of EVO756 in Adults With Migraine
Phase 2Completed 8 May 2025 A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Phase 2Completed 29 May 2026 Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Phase 2Completed 23 Jul 2026 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow EVO756

Following is part of Solo: you see every change to EVO756 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in